Home / Companies / Shanghai Junshi Biosciences Co., Ltd. / 20 Oct 2023
Shanghai Junshi Biosciences Co., Ltd.: meeting of 20 Oct 2023
Votes reported on Form N-PX, item by item
31 Form N-PX filers reported votes at the Shanghai Junshi Biosciences Co., Ltd. meeting of 20 Oct 2023. Their records fall into 4 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
1 nominee; 98.6% of reported votes for; one filer withheld from or voted against at least one nominee.
74 vote records from 31 filers. 1 of the 31 filers that marked the item either way voted against management.
One filer reported a share count too large to be the holding described. That figure is left out of the share split below; the count of filers includes it. How that is decided
DIRECTOR ELECTIONSSecurity holder
Director elections (nominees put forward by security holders)
1 nominee; 100.0% of reported votes for; no filer withheld from or voted against at least one nominee.
54 vote records from 24 filers. 0 of the 24 filers that marked the item either way voted against management.
One filer reported a share count too large to be the holding described. That figure is left out of the share split below; the count of filers includes it. How that is decided
EXTRAORDINARY TRANSACTIONSIssuer
EXTRAORDINARY TRANSACTIONS: management items
Management items in this category are shown together; filers word and number them differently.
61 vote records from 29 filers. 0 of the 29 filers that marked the item either way voted against management.
One filer reported a share count too large to be the holding described. That figure is left out of the share split below; the count of filers includes it. How that is decided
OTHERIssuer
OTHER: management items
Management items in this category are shown together; filers word and number them differently.
13 vote records from 5 filers. No filer marked a management recommendation, so no against-management figure is reported. 5 filers reported this item without a management mark.
How the largest families voted
| Family | 1. Directors | 2. Directors |
|---|---|---|
| Vanguard | For | For |
| BlackRock and iShares | For | For |
| Fidelity | For | For |
| State Street and SPDR | For | For |
| Franklin Templeton | For | For |
| Charles Schwab | For | No report |
| Nuveen and TIAA | For | For |
| John Hancock and Manulife | For | No report |
| Morgan Stanley, Eaton Vance and Calvert | Against * | For |
| J.P. Morgan | For | No report |
| PGIM and Prudential | For | For |
| Jackson National funds | For | No report |
| Northern Trust and FlexShares | For | For |
| Lincoln Financial | For | For |
| Voya | For | For |
| BNY Mellon | For | For |
| Pacific Life funds | For | For |
| Global X | For | No report |
| Macquarie and Delaware Funds | For | For |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Shanghai Junshi Biosciences Co., Ltd. meeting?
31 Form N-PX filers reported votes at the meeting of 20 Oct 2023. The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Shanghai Junshi Biosciences Co., Ltd. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Shanghai Junshi Biosciences Co., Ltd.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Shanghai Junshi Biosciences Co., Ltd. with a meeting date within three days of 20 Oct 2023. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.